The US Food and Drug Administration has accepted a biologics license application for a long-acting antibody for the prevention of lower respiratory tract infections caused by the respiratory syncytial virus, according to the developers of the antibody.If approved, it could be available for use in some infants and toddlers later this year.
#united-states #disease-control #european-union #astrazeneca #authorization #executive-vice-president #hospitalization #severe-illness
[
add
]
[
|
|
...
]